Click here to check out calendar of events for the month of March.
Warning: ftp_get(): Error opening D:/WEBROOT/VHOSTS/alpha.mscare.org/httpdocs/cmsc/cache/healthnewsfeed.dat in D:\WEBROOT\VHOSTS\alpha.mscare.org\httpdocs\cmsc\modules\mod_healthdaynewsfeed.php on line 44
MS News from HealthDay:
CMSC News:
For a complete listing of CMSC News, please click here.
- March 16, 2011 - Multiple Sclerosis Emerging Therapies Collaborative Launched
- March 15, 2011 - 2010 Revisions to the McDonald Criteria for Diagnosing MS Published
- January 31, 2011 - Six month update on the initial Society sponsored CCSVI research grants
- December 23, 2010 - A Sad Loss for the MS Community: Dr. Hillel Panitch, MD passed away
- December 20, 2010 - National MS Society Leads Way in 2010 in Cutting Edge Research to Stop MS, Restore Function and End MS Forever
- December 15, 2010 - Announcing National MS Society's New Chief Research Officer
- December 13, 2010 - Individual Mandate in Healthcare Reform Law Ruled Unconstitutional by Federal Judge
- November 1, 2010 - Neurology Reviews Launches MS Comprehensive Care Web site
- September 29, 2010 - House of Representatives Passed H.R. 1362, The National Neurological Diseases Surveillance System Act
- September 27, 2010 - Letter from Congressman Patrick Kennedy: On Wednesday, September 29, 2010, the Oversight and Government Reform Committee will hold a hearing entitled “From Molecules to Minds: The Future of Neuroscience Research and Development.”
- September 22, 2010 - CMSC President's statement on the approval of Gilenya
CMSC INForMS (Industry News for MS):
For a complete listing of CMSC Industry News for MS, please click here.
- April 28, 2011 - Merck Serono Provides $1.5M Grant to Massachusetts General Hospital
- April 25, 2011 - XenoPort Announces FDA Agreement on a Special Protocol Assessment for a Pivotal Phase 3 Clinical Trial of Arbaclofen Placarbil for Spasticity in MS Patients
- April 21, 2011 - UCSF Study Revisits First Clinical Trial to Treat Multiple Sclerosis Decades Later
- April 19, 2011 - Biogen Idec Receives Positive Opinion from the CHMP and Authorisation from Health Canada on Avonex Pen
- April 18, 2011 - Scripps Research Scientists Develop Compound That Effectively Halts Progression of Multiple Sclerosis
- April 18, 2011 - CHMP Recommends Updating Tysabri Labeling with anti-JC Virus Antibody Status as a Third Factor to Further Stratify Risk of PML
- April 12, 2011 - Oral Laquinimod for Multiple Sclerosis Treatment Significantly Reduced Disease Activity and Disability Progression While Providing Good Safety and Tolerability
- April 11, 2011 - Novartis Therapy Gilenyatm Reduced the Risk of MS Disability Progression Regardless of Treatment History Or Disease Severity, New Analysis Shows
- April 11, 2011 - Acorda Therapeutics Presents New AMPYRA (dalfampridine) Data Analyses on Walking Improvement in Multiple Sclerosis at AAN Annual Meeting
- April 11, 2011 - Biogen Idec Announces Positive Top-Line Results from the First Phase 3 Trial Investigating Oral BG-12 (DIMETHYL FUMARATE) in Multiple Sclerosis
- April 4, 2011 - Avanir Pharmaceuticals Announces Filing of IND for AVP-923 for the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis
- March 28, 2011 - Adeona's Multiple Sclerosis Trial Receives $409,426 Grant
- March 22, 2011 - Sativex recommended for approval in all six European countries
- March 21, 2011 - Novartis Receives European Commission Approval for Gilenya, the First Oral Multiple Sclerosis Treatment for Use in the EU
- March 16, 2011 - CIGNA and EMD Serono Team to Fight Multiple Sclerosis Under First Outcomes-Based Specialty Medication Contract
- March 14, 2011 - Purdue Research May Lead to Therapy That Delays Onset, Reduces Severity of MS Symptoms
- March 10, 2011 - First oral treatment for people with multiple sclerosis approved in Canada
- March 7, 2011 - Stem Cell Therapeutics Corp. Announces Commencement of MS Research Program
- March 2, 2011 - EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
- February 16, 2011 - Reimbursement granted for Sativex in Spain, for the treatment of spasticity in multiple sclerosis
- February 10, 2011 - Merck Serono Launches UniteMS.net - A Pioneering Social Network and Online Resource for the Multiple Sclerosis Community
- February 3, 2011 - New Analysis Published in Multiple Sclerosis Journal Recommends Intrathecal Baclofen (Itb) Therapy for Ms Patients Suffering From Spasticity
- January 28, 2011 - Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis
- January 21, 2011 - Novartis International AG (CH) - Novartis Gains Positive CHMP Opinion for Gilenya, First Oral Multiple Sclerosis Treatment Recommended for Approval in the European Union
- January 21, 2011 - Acorda Therapeutics Statement on European CHMP Decision on Fampyra
- January 21, 2011 - Merck Serono Announces Outcome of Its Request for Reexamination of CHMP Opinion for Cladribine Tablets in MS
- January 10, 2011 - Safety Alert: Certain Alcohol Pads/Swabs Recalled by FDA - anyone taking injectable medication should check package to see if they were made by Triad Group
- January 5, 2011 - Opexa Successfully Completes End-of Phase 2 Meetings with FDA; In Position for Pivotal Study of Tovaxin
- December 27, 2010 - Biotech Foundations: Myelin Repair Group Works to Develop Drugs, Cure MS
- December 24, 2010 - Teva Pharmaceutical receives complete response letter from FDA for lower-volume Glatiramer Acetate sNDA
- December 13, 2010 - Merck Serono and San Raffaele Scientific Institute to Collaborate on Research in Neurodegenerative Diseases
- December 9, 2010 - Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
- November 26, 2010 - Merck Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis
- November 25, 2010 - Multiple Sclerosis Patient Experiences Improved Vision on TYSABRI
- November 23, 2010 - FDA Approves Movement Disorder Drug From CNS Therapeutics: GABLOFEN® (baclofen injection) for the Treatment of Severe Spasticity
- November 17, 2010 - Merck KGaA: Enrollment Completed for ORACLE MS Study of Cladribine Tablets in Patients at Risk of Developing MS
- November 17, 2010 - Additional Phase 3 Clinical Trial Data Published in Annals of Neurology Showing Dalfampridine Extended Release Tablets Improved Walking Ability in People with Multiple Sclerosis
- November 11, 2010 - Information on new BETASERON (interferon beta - 1b) Injection Syringe
- October 29, 2010 - FDA Approves Nuedexta™ to Treat Episodes of Uncontrollable Laughing or Crying, a Symptom That Can Occur in People with MS and Other Disorders
- October 26, 2010 - Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
- October 26, 2010 - DIME Launches MS Patient Resources iPhone and iPod Touch App
- October 25, 2010 - REFLEX Study Results Show Treatment with Rebif Delays Conversion to MS in Patients with First Clinical Signs of the Disease
- October 16, 2010 - Data Further Supporting Anti-JC Virus Antibody Assay Presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- October 16, 2010 - Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
- October 16, 2010 - Early Initiation of Treatment with Copaxone® Provides Greater Effects in Delaying Conversion to Clincially Definite MS
- October 16, 2010 - New Data Evaluating Laquinimod for the Treatment of Multiple Sclerosis Demonstrate Neuroprotective Effects
- October 15, 2010 - Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
- October 15, 2010 - Acorda therapeutics Announces Data On Ampyra (Dalfampridine) Presented at 26th Congress of European Committee for Treatment and Research in Multiple Sclerosis
- October 15, 2010 - Genzyme’s Alemtuzumab Shows Sustained Reduction in Relapses and Disability in Five-Year Review of MS Patients from Phase 2 Trial
- October 7, 2010 - Novartis committed to supporting patients and healthcare professionals with education programs and support services that enhance access to Gilenya
- September 27, 2010 - Imaging study provides new view of multiple sclerosis
- September 24, 2010 - New findings on multiple sclerosis -- immune cells also attack neurons directly
- September 22, 2010 - Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
- September 17, 2010 - Data Published in Journal of Neuroimmunology Suggest Anti-Inflammatory Role for Lead VBL Therapeutics Compound in CNS Inflammatory Diseases
- September 10, 2010 - Novartis International AG (CH) - Novartis Announces Russian Regulatory Approval for Gilenya, a Once-Daily Oral Multiple Sclerosis Therapy and First in a New Class
- September 10, 2010 - Genmab Announces Results of Ofatumumab Phase II Study in Multiple Sclerosis
- September 1, 2010 - MS LifeLines Reaches Milestone of Servicing One Million In-Bound Calls
- July 6, 2010 - Genmab Announces Interim Results of Ofatumumab Phase II Study in Multiple Sclerosis
- July 1, 2010 - Compugen Discovered Protein Shown to Abolish Recurring Relapses in Multiple Sclerosis Animal Model
- June 10, 2010 - FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS
- June 8, 2010 - Bayer Introduces myBETAapp iPhone Application
|
